Construction and validation of a cuproptosis-related prognostic model for glioblastoma

• Published in: Frontiers in immunology Vol. 14; p. 1082974
• Main Authors: Zhang, Bohong, Xie, Lin, Liu, Jiahao, Liu, Anmin, He, Mingliang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.02.2023
• Subjects: Apoptosis; Blotting, Western; cuproptosis; Glioblastoma; Humans; Immunology; Nomograms; Prognosis; risk score model; Tumor Microenvironment; glioblastoma; tumor microenvironment; cuproptosis; risk score model; prognosis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1082974

Cuproptosis, a newly reported type of programmed cell death, takes part in the regulation of tumor progression, treatment response, and prognosis. But the specific effect of cuproptosis-related genes (CRGs) on glioblastoma (GBM) is still unclear. The transcriptome data and corresponding clinical data of GBM samples were downloaded from the TCGA and GEO databases. R software and R packages were used to perform statistical analysis, consensus cluster analysis, survival analysis, Cox regression analysis, Lasso regression analysis, and tumor microenvironment analysis. The mRNA and protein expression levels of model-related genes were detected by RT-qPCR and Western blot assays, respectively. The expression profile of CRGs in 209 GBM samples from two separate datasets was obtained. Two cuproptosis subtypes, CRGcluster A and CRGcluster B, were identified by consensus cluster analysis. There were apparent differences in prognosis, tumor microenvironment, and immune checkpoint expression levels between the two subtypes, and there were 79 prognostic differentially expressed genes (DEGs). According to the prognostic DEGs, two gene subtypes, geneCluster A and geneCluster B, were identified, and a prognostic risk score model was constructed and validated. This model consists of five prognostic DEGs, including PDIA4, DUSP6, PTPRN, PILRB, and CBLN1. Ultimately, to improve the applicability of the model, a nomogram was established. Patients with GBM in the low-risk cluster have a higher mutation burden and predict a longer OS than in the high-risk group. Moreover, the risk score was related to drug sensitivity and negatively correlated with the CSC index. We successfully constructed a cuproptosis-related prognostic model, which can independently predict the prognosis of GBM patients. These results further complement the understanding of cuproptosis and provide new theoretical support for developing a more effective treatment strategy.